Neuphoria Therapeutics (NEUP) vs Universe Pharmaceuticals (UPC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Universe Pharmaceuticals (UPC) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 55.8% versus a loss of 81.8%. Universe Pharmaceuticals is the larger company by market cap ($21.0 million vs $18.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEUP | UPC |
|---|---|---|
| Share price | $3.35 | $4.18 |
| Market cap | $18.13M | $21.00M |
| 1-day change | -2.05% | -5.00% |
| YTD return | -13.66% | +9.71% |
| 1-year return | -81.76% | -55.81% |
| 5-year return | — | -99.95% |
| EPS (TTM) | $-3.06 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.21 | $17.96 |
| 52-week low | $3.19 | $2.00 |
| Distance from 52-week high | -82.56% | -76.73% |
| Analyst consensus | none | — |
| Average volume | 161.66K | 788.87K |
| Shares outstanding | 5.41M | 5.01M |
| Employees | 1 | 216 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UPC has outperformed NEUP by 25.9 percentage points over the past year.
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Healthcare · Biotechnology · 1 employees
About Universe Pharmaceuticals
UPC stock →Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.
Healthcare · Drug Manufacturers - Specialty & Generic · 216 employees
NEUP vs UPC FAQ
Which is bigger, Neuphoria Therapeutics or Universe Pharmaceuticals?
Universe Pharmaceuticals (UPC) is larger, with a market capitalization of $21.00M compared with $18.13M for Neuphoria Therapeutics (NEUP).
Which stock has performed better over the past year, NEUP or UPC?
UPC returned -55.81% over the past 12 months, compared with -81.76% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are Neuphoria Therapeutics and Universe Pharmaceuticals in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Neuphoria Therapeutics and Drug Manufacturers - Specialty & Generic for Universe Pharmaceuticals.